OncoMatch/Clinical Trials/NCT05284552
Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer
Is NCT05284552 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Tinzaparin Injectable Solution for epithelial ovarian cancer.
Treatment: Tinzaparin Injectable Solution — Background: Previous findings have indicated antineoplastic properties of tinzaparin (Innohep®), a commonly used anti-coagulant. Earlier studies have mainly investigated the antineoplastic effects of tinzaparin in animal models and in human cell-lines. In this pilot study the aim is to examine the potential antitumoral effects of tinzaparin in vivo in women with epithelial ovarian cancer (EOC). Study objectives: Primary objective: The primary objective of the study is to evaluate the effects of tinzaparin on changes in levels of CA-125 in EOC patients who receive neoadjuvant chemotherapy (NACT). Secondary objectives: The secondary objective of the study is to explore the impact of tinzaparin on the dynamic of a spectrum of immunological and coagulation factors in EOC patients who receive NACT. Besides, the compliance of tinzaparin injections and adverse events caused by tinzaparin will be described.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Disease stage
Required: Stage FIGO III, FIGO IV (FIGO)
Grade: high grade serous carcinoma
FIGO stage III-IV disease. Histology diagnosis of either high grade serous carcinoma, endometrioid carcinoma or clear cell carcinoma.
Performance status
WHO 0–1
Demographics
Prior therapy
Cannot have received: heparin
Concomitant treatment with heparins, low molecular weight heparins, warfarin or nonvitamin K antagonist oral anticoagulants. Platelet inhibitors are allowed.
Cannot have received: heparin
Treatment with heparins, low molecular weight heparins or non-vitamin K antagonist oral anticoagulants within the last year.
Cannot have received: platinum single regimen
Platinum single regimen
Cannot have received: treatment for other known malignancy
Exception: except basal cell carcinoma
Treatment for other known malignancy within the last year (except basal cell carcinoma)
Lab requirements
Blood counts
Platelets <100 x10^9/L (analyzed no more than 14 days before start of treatment with investigational product) [excluded]
Kidney function
Estimated glomerular filtration rate (E-GFR) <30ml/min (analyzed no more than 14 days before start of treatment with investigational product) [excluded]
Estimated glomerular filtration rate (E-GFR) <30ml/min (analyzed no more than 14 days before start of treatment with investigational product); Platelets <100 x10^9/L (analyzed no more than 14 days before start of treatment with investigational product)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05284552 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage FIGO III or FIGO IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages